Article
Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma.
1 Feb 1996
Abstract excerpt
PURPOSE: The usual therapy of osteosarcoma is neoadjuvant chemotherapy, followed by surgery, then by postoperative chemotherapy. There is no prognostic factor to predict, at diagnosis, the histologic response and final outcome. Inactivation of the retinoblastoma-susceptibility gene RB is associated with the pathogenesis of several human cancers. In primary osteosarcomas, loss of heterozygosity (LOH) at the RB...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
